Coya Therapeutics reported a material QoQ revenue increase in QQ2 2024, underscoring early monetization activity even as the business remains heavily pre-commercial and R&D-intensive. Revenue rose to $3.425 million, up from Q1 2024 levels, with gross profit matching revenue and a 100% gross margin given the nature of early-stage biotech revenue and minimal cost of revenue. However, operating expenses of $6.656 million produced an EBITDA loss of $3.229 million and a net loss of $2.892 million for the quarter, reflecting the company’s continued emphasis on pipeline progression over near-term profitability.
The balance sheet remains notably liquidity-rich for a biotech at this stage, with $36.576 million of cash and equivalents at quarter-end and no outstanding debt. Strong liquidity plus a positive financing contribution of $5.149 million helped produce a modestly higher quarterly cash balance despite ongoing operating burn. The company’s cash position provides runway to advance multiple pipeline programs, including COYA 101 (autologous Treg product candidate for ALS in Phase 2a), and IND-enabling activities for COYA 301 and COYA 302, while preclinical COYA 201 and COYA 206 continue to be evaluated. Investors should monitor pipeline milestones, potential collaboration opportunities, and any shifts in burn rate as the company progresses through its development timeline.